Lack of LCAT Reduces the LPS-neutralizing Capacity of HDL and Enhances LPS-induced Inflammation in Mice
Overview
Biophysics
Authors
Affiliations
HDL has important immunomodulatory properties, including the attenuation of lipopolysaccharide (LPS)-induced inflammatory response. As lecithin-cholesterol acyltransferase (LCAT) is a critical enzyme in the maturation of HDL we investigated whether LCAT-deficient (Lcat(-/-)) mice present an increased LPS-induced inflammatory response. LPS (100μg/kg body weight)-induced cytokine response in Lcat(-/-) mice was markedly enhanced and prolonged compared to wild-type mice. Importantly, reintroducing LCAT expression using adenovirus-mediated gene transfer reverted their phenotype to that of wild-type mice. Ex vivo stimulation of whole blood with LPS (1-100ng/mL) showed a similar enhanced pro-inflammatory phenotype. Further characterization in RAW 264.7 macrophages in vitro showed that serum and HDL, but not chylomicrons, VLDL or the lipid-free protein fraction of Lcat(-/-) mice, had a reduced capacity to attenuate the LPS-induced TNFα response. Analysis of apolipoprotein composition revealed that LCAT-deficient HDL lacks significant amounts of ApoA-I and ApoA-II and is primarily composed of ApoE, while HDL from Apoa1(-/-) mice is highly enriched in ApoE and ApoA-II. ApoA-I-deficiency did not affect the capacity of HDL to neutralize LPS, though Apoa1(-/-) mice showed a pronounced LPS-induced cytokine response. Additional immunophenotyping showed that Lcat(-/-) , but not Apoa1(-/-) mice, have markedly increased circulating monocyte numbers as a result of increased Cd11b(+)Ly6C(med) monocytes, whereas 'pro-inflammatory' Cd11b(+)Ly6C(hi) monocytes were reduced. In line with this observation, peritoneal macrophages of Lcat(-/-) mice showed a markedly dampened LPS-induced TNFα response. We conclude that LCAT-deficiency increases LPS-induced inflammation in mice due to reduced LPS-neutralizing capacity of immature discoidal HDL and increased monocyte number.
Morvaridzadeh M, Zoubdane N, Heshmati J, Alami M, Berrougui H, Khalil A Nutrients. 2024; 16(5).
PMID: 38474781 PMC: 10935171. DOI: 10.3390/nu16050653.
Hong B, Zheng J, Romo E, Agus J, Tang X, Arnold C Curr Dev Nutr. 2023; 7(12):102041.
PMID: 38130330 PMC: 10733676. DOI: 10.1016/j.cdnut.2023.102041.
Dyslipidemia in rheumatoid arthritis: the possible mechanisms.
Yan J, Yang S, Han L, Ba X, Shen P, Lin W Front Immunol. 2023; 14:1254753.
PMID: 37954591 PMC: 10634280. DOI: 10.3389/fimmu.2023.1254753.
Bogomolov A, Filonov S, Chadaeva I, Rasskazov D, Khandaev B, Zolotareva K Int J Mol Sci. 2023; 24(10).
PMID: 37240358 PMC: 10219026. DOI: 10.3390/ijms24109010.
Oria R, Freitas R, Roque C, Nascimento J, Paula Silva A, Malva J Pharmaceutics. 2023; 15(4).
PMID: 37111572 PMC: 10141726. DOI: 10.3390/pharmaceutics15041086.